BPH Global Names Chief Scientific Officer to Fast-Track Seaweed R&D to Market

BPH Global has appointed Ms Ifat Mazouz as Chief Scientific Officer (CSO), effective 25 May 2026, transitioning her from a part-time Advisory Board role to an executive leadership position. The appointment reflects the company’s strategic focus on accelerating commercialisation of its R&D portfolio and converting research programs into revenue-generating opportunities. Ms Mazouz brings nearly two decades of international experience in marine biotechnology, aquaculture systems, and product development.

BPH Global appoints Chief Scientific Officer to drive R&D commercialisation

Ms Mazouz’s transition from advisory capacity to full-time executive marks a shift in BPH Global’s operational focus. The appointment signals the company’s intent to move from research phase toward commercial execution, with dedicated leadership accountable for transforming R&D assets into market-ready products.

The CSO will assume full responsibility for coordinating and executing the company’s research and development activities. Her mandate centres on delivering commercial outcomes rather than maintaining research programs as standalone initiatives. This structural change positions BPH Global (ASX: BP8) to accelerate the progression of priority projects toward near-term commercialisation, including the company’s kefir drink product in powdered form.

Ms Mazouz brings particular expertise in translating R&D programs from concept through to commercial deployment, with a proven track record in scaling biotechnology products to market readiness.

What does a Chief Scientific Officer do?

A Chief Scientific Officer sits at the intersection of scientific development and business strategy. The role differs from a research director or laboratory head by carrying explicit accountability for commercial pathways, not just research outcomes.

For small-cap companies transitioning from R&D to revenue generation, a dedicated CSO ensures research programs have clear commercialisation routes rather than remaining academic exercises. This matters because early-stage biotechnology and aquaculture companies often accumulate research assets without structured plans to convert them into products or licensing agreements.

In BPH Global’s context, the company has developed an R&D portfolio centred on seaweed innovation that requires dedicated executive focus to reach market. The CSO appointment creates a clear line of accountability for commercial execution, distinct from advisory input or part-time consultancy arrangements.

For investors in early-stage companies, a dedicated CSO appointment often signals the transition from “science project” to “commercial enterprise,” marking a shift in capital allocation priorities toward revenue-generating activities.

Commercial mandate and immediate priorities

Ms Mazouz will hold explicit responsibility for converting BPH Global’s research initiatives into commercial outcomes. Her role scope includes:

• Leading progression of priority R&D projects toward near-term commercialisation
• Overseeing in-house and outsourced R&D programs to ensure alignment with commercial objectives
• Acting as primary liaison between BPH Global and its R&D partners
• Identifying and advancing new opportunities with strong commercial potential
• Supporting investor engagement through clear articulation of the commercial value of BPH Global’s technologies

The immediate focus centres on advancing the kefir drink product in powdered form toward commercialisation. This product has been in development as part of the company’s broader seaweed innovation program.

The structure is designed to integrate R&D activities with commercial strategy, enabling efficient transition from scientific development to market-ready products. Ms Mazouz will coordinate both in-house research teams and external R&D consultants, ensuring all programs maintain clearly defined pathways to market, scalability, and revenue generation.

The explicit commercial mandate differentiates this appointment from a pure research role. Ms Mazouz is accountable for revenue pathways, not just scientific outcomes, with performance measured against commercialisation milestones rather than research publications or patent applications.

Director commentary

Managing Director Mathew Leonard

“Ms Mazouz’ appointment is yet another key milestone that BPH Global has achieved over past months, and illustrates our commitment to becoming the pre-eminent company in seaweed innovation and commercialisation. We are so pleased to welcome Ms Mazouz at the commencement of what I firmly believe will be a successful period of innovation and growth for our Company.”

The forward-looking language references expectations for project progress in coming months as the CSO structure becomes operational.

Transition and operational arrangements

Ms Mazouz will be based in Melbourne, Australia once an appropriate work visa is obtained. The company will undertake the visa application process on her behalf.

During the interim period while the visa is processed, Ms Mazouz will operate from Southeast Asia while performing her CSO duties. The current consultancy arrangement will convert to a formal executive employment agreement upon visa grant.

The appointment is effective 25 May 2026 regardless of visa timing, ensuring commercial momentum is not delayed by administrative processing. Ms Mazouz will relocate to Australia as soon as practicable following visa approval.

Strategic context for BPH Global

This appointment positions BPH Global within its stated ambition to become “the pre-eminent company in seaweed innovation and commercialisation,” according to Managing Director commentary. The emphasis on commercialisation reflects a strategic shift toward converting the R&D portfolio into revenue-generating opportunities.

The company has accumulated research assets centred on seaweed applications, including the kefir drink product currently in development. The CSO appointment creates dedicated executive capacity to advance these projects from research phase to commercial deployment.

The investment thesis for BPH Global shifts from “what could they develop” to “when can they commercialise” with the addition of execution capability to the existing R&D asset base. The company has indicated it expects to provide shareholders with project progress updates in coming months as the CSO structure becomes operational.

This appointment represents the latest in what management describes as a series of milestones achieved over recent months, suggesting accelerating operational momentum as the company transitions from research-focused activities toward commercial execution.

Want the Next Biotech Breakthrough in Your Inbox?

Join 20,000+ investors getting FREE breaking ASX news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start receiving alerts the moment market-moving announcements hit the ASX—before the market reacts.